The Dow Chemical Company

Other

Cartilast Ii LLC

Cartilast Corporation

Eugene R Moore

Thomas D Traugott

Michael T Malanga

George J Quarderer, Jr

Clark J Cummings

David C McDonald

Brian D Dalke

Roger L Briggs

Duane B Priddy, Sr

David Roger Moore

Robert A Hay, Ii

Gary D Parsons

Robert M Nowak

Danil Tirtowidjojo

Dan Tirtowidjojo

Wen H Tong

Norman A Lefevre

Kenneth J Guilette

Joseph Willner

Thomas K Christianson

Ronald L Wence

Richard Hoffman

John S Kowalczyk

Maxmilian J deFreitas

Jon T Goodman

Tom E Wessel

John W Lee

Rudolph Lindsey, Jr

Paul C Balliet

Gary M Poindexter

A method for the treatment of a person suffering from neurodegenerative disease such as Alzheimer's, Parkinson's, or Huntington's disease by treating the patient's brain, over the span of one year or less with a plurality of doses of ionizing radiation, each dose being more than 2.5 mJ/kg but less than 150 mJ/kg with the total dose being more than 10 mJ/kg but less than 400 mJ/kg.

Treatment of alzheimer's disease

The instant invention is the storage of Type II collagen containing tissue in carbonated water. Such Type II collagen is useful for alleviating the symptoms of arthritis in mammals as well as the treatment of arthritis in mammals. Such Type II collagen is also useful for the prevention of arthritis in mammals. The instant invention is also a method for the preparation of a nutritional supplement that includes the steps of: (a) separating water-insoluble undenatured Type II collagen containing animal tissue from animal tissue not containing Type II collagen; (b) subdividing and sterilizing said tissue under conditions which do not change the original structure of the Type II collagen to produce a subdivided and sterilized product; (c) packaging the subdivided and sterilized product in carbonated water.

Preservation of the biological activity of undenatured type II collagen

The present invention is the storage of biologically active natural ingredients in carbonated water. In a specific embodiment, the present invention is the storage in carbonated water of animal tissue containing type II collagen. Such type II collagen is useful for alleviating the symptoms of arthritis in mammals as well as the treatment of arthritis in mammals. Such type II collagen is also useful for the prevention of arthritis in mammals. The present invention is also a method for the preparation of a nutritional supplement that includes the steps of: (a) separating animal tissue containing water-insoluble, undenatured type II collagen from animal tissue not containing type II collagen; (b) subdividing and sterilizing said tissue under conditions which do not change the original structure of the type II collagen to produce a subdivided and sterilized product; (c) packaging the subdivided and sterilized product in carbonated water.

The present invention relates to the formation of low volatile anhydride-containing aromatic vinyl polymers by polymerizing the half ester of the anhydride with a vinyl aromatic monomer followed by devolatilizing the half-ester and reforming the anhydride at elevated temperatures and reduced pressures.

Devolatilization of anhydride polymers

This invention is a process to manufacture high quality vinyl aromatic polymer that is essentially free of unreacted vinyl aromatic monomer using retarded anionic polymerization wherein the retardant is insoluble and can be removed from the polymerization at an intermediate stage so that the polymerization can be carried to completion in the absence of the retardant.

Retarded anionic polymerization of vinyl aromatic monomers using insoluble or heterogeneous retardants

The extremely rapid anionic polymerization rate of polystyrene has made polymerization difficult to control and has prevented large-scale development. This invention uses batch polymerization to utilize the rapid rate of polymerization to complete polymerization from zero to 100% conversion in minutes and turns this rapid rate into an advantage. Polystyrene itself is used as a heat sink to limit and control the maximum temperature reached during polymerization. Adiabatic polymerization increases the polymer temperature to the desired processing temperature of the polymer for either removal of volatile compounds or for direct pellet formation when no solvent is employed. The polystyrene to be used as a heat sink is added either as pellets or is first formed at a low controllable temperature. Extremely low levels of residual monomer are found in the product. This invention also demonstrates techniques to prevent gel formation or to reduce formation to an acceptable level.

Anionic process design for rapid polymerization of polystyrene without gel formation and product produced there from

The present invention is directed to a process for producing a high molecular weight condensation polymer by removing unwanted by-product(s) from a polycondensation equilibrium reaction mixture using a centrifugal force device equipped with a vacuum.

Process for producing a high molecular weight condensation polymer

A method for devolatilization of a thermoplastic polymer containing at least one volatile component which includes the following three steps: heating the thermoplastic polymer so that the thermoplastic polymer is a heated liquid or molten thermoplastic polymer, flowing the heated liquid thermoplastic polymer through a packed bed liquid-gas contactor by centrifugal force, and flowing a stripping gas through the packed bed countercurrent to the flow of the heated liquid thermoplastic polymer so that the volatile component volatilizes into the stripping gas from the heated liquid thermoplastic polymer by gas-liquid contacting in the packed bed; and an apparatus therefor.

Centrifugal method and apparatus for devolatilizing polymers

This invention provides a method for alleviating the symptoms of arthritis in mammals which comprises orally administering a composition obtained by separating water-insoluble undenatured Type II collagen containing animal tissue from animal tissue not containing Type II collagen, subdividing and sterilizing said tissue under conditions which do not change the original structure of the Type II collagen, in an amount effective and for time effective to alleviate such symptoms.

Method for alleviating the symptoms of arthritis in mammals

This invention provides a composition useful as an edible supplement for alleviating the symptoms of arthritis for oral consumption by mammals, said composition comprising animal tissue containing water-insoluble Type II collagen, which has been separated from non-Type II collagen containing tissue and has been sterilized in subdivided form without changing the original structure of the Type II collagen.

Product for alleviating the symptons of arthritis in mammals

This invention provides a method of preparing animal tissue containing water-insoluble undenatured Type II collagen for use in treating autoimmune arthritis, particularly rheumatoid arthritis.

Method for preparing animal tissue for use in alleviating the symptoms

This invention provides a therapeutic pill comprising animal tissue containing a therapeutic amount of Type II collagen and a method of preparing animal tissue containing Type II collagen for treatment of Rheumatoid Arthritis in humans.

Growing community of inventors

Midland, MI, United States of America

Eugene R Moore